Celltrion Nasdaq

Celltrion Inc., South Korea’s largest biosimilar maker, said on Monday that it completed the establishment of a local subsidiary in Vietnam....

Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ing...

Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract developmen...

South Korea’s biosimilar maker Celltrion Inc. will venture into the contract development and manufacturing organization (CDMO) market, the com...

Yanolja Co., South Korea’s leading travel and accommodation booking platform operator, may delay its Nasdaq initial public offering plan due t...

Korea Investment Management Co. said on Thursday that the net assets of its ACE US Nasdaq 100 Exchange-Traded Fund (ETF) had surpassed 1 trillion wo...

South Korea’s largest biosimilar maker Celltrion Inc. said on Friday that it has scrapped a plan to merge with Celltrion Pharm Inc., an R&...

South Korea’s top travel and accommodation booking platform operator Yanolja Co. is seeking to streamline and restructure its affiliates to bo...

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...

Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, ...

Foreigners and institutional investors in the South Korean stock market picked biotechs as their favorite shares in hopes of a biopharma stock jump ...

South Korean biosimilar maker Celltrion Inc. said on Monday that its subcutaneous injection formulation for autoimmune diseases, Zymfentra (inflixim...

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...

South Korea’s largest biosimilar maker Celltrion Inc. said on Tuesday that its third plant in Sondgo, west of Seoul, is undergoing process val...

South Korea's biopharmaceutical company Celltrion Inc. said on Wednesday that its subcutaneous autoimmune disease treatment Remsima SC has surpassed...

Webtoon Entertainment Inc., South Korean tech giant Naver Corp.'s online comics platform, said on Thursday that it will raise $315 million by issuin...

South Korea’s online portal giant Naver Corp. is planning to list its Los Angeles-based affiliate Webtoon Entertainment Inc. on the Nasdaq thi...

Superior Essex Inc. (SPSX), the world’s top magnet wire provider under South Korea’s LS Group, is mulling an initial public offering in ...

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...

Celltrion Inc. and SK Biopharmaceuticals Co. are witnessing improving sales revenue and profitability by selling their products through their own ma...

K Enter Holdings Inc., an umbrella entity of South Korea-based entertainment companies creating original entertainment content and managing related ...

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...

South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) t...

Mirae Asset Global Investments Co., one of the largest asset managers in South Korea, said on Thursday that its exchange-traded fund (ETF) TIGER US ...

South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...

South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...